• Article
  • | |
  • Metrics
  • |
  • Reference [23]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    AIM: To assess the cost-effectiveness of autologous retinal pigment epithelium and choroid translocation (PATCH) in neovascular age-related macular degeneration (AMD). METHODS: Visual acuity and complication rates of published patient series were used to determine the incremental utility of treatment for the patient. The utility data applied assume that the better eye was affected. Comparator was a meta-analysis of recent control groups, in which patients received best supportive care. To assess cost-effectiveness, costs per quality adjusted life years (QALYs) and costs of avoiding low vision ("legal blindness", i.e. ≤20/200) were calculated. Costs were based on a German sick fund perspective and in a scenario on US costs. Robustness of the model was investigated by univariate and probabilistic multivariate sensitivity analysis (PSA). RESULTS: Cost-utility analysis showed surgery to be the dominant ("cost-saving") strategy for Germany and for the US in both, cost-effectiveness and cost-utility analysis (costs per QALY). In the sensitivity analysis the intervention remained dominant or cost-effective in all scenarios investigated. Clinical outcomes and duration of modeling were the most influential factors in the sensitivity analyses. CONCLUSION: Therapy of neovascular AMD by PATCH is a cost-effective treatment option for selected patients, who are not well suitable for other current treatment options.

    Reference
    1 Lotery A, Xu X, Zlatava G, Loftus J. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol 2007;91(10):1303-1307
    2 Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monès J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 2007;125(9):1249-1254
    3 Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR.The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol 2006;17(3):257-266
    4 Knauer C, Pfeiffer N. Blindness in Germany--today and in 2030. Ophthalmologe 2006;103(9):735-741
    5 Neubauer AS, Welge-Lüssen UC, Thiel MJ, Alge C, Priglinger SG, Hirneiss C, Ulbig MW, Kampik A.Tele-screening for diabetic retinopathy with the retinal thickness analyzer. Diabetes Care 2003;26(10):2890-2897
    6 Schrader WF. Age-related macular degeneration: a socioeconomic time bomb in our aging society. Ophthalmologe 2006;103(9):742-748
    7 Maaijwee K, Heimann H, Missotten T, Mulder P, Joussen A, van Meurs J. Retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: long-term results. Graefes Arch Clin Exp Ophthalmol 2007;245(11):1681-1689
    8 Heussen FM, Fawzy NF, Joeres S, Lux A, Maaijwee K, Meurs JC, Kirchhof B, Joussen AM.Autologous translocation of the choroid and RPE in age-related macular degeneration: 1-year follow-up in 30 patients and recommendations for patient selection. Eye 2008;22(6):799-807
    9 Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431
    10 Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432-1444
    11 von der Schulenburg J, Vauth C, Mittendorf T, Greiner W. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. Eur J Health Econ 2007;8 (Suppl) 1:S5-31
    12 Smiddy WE.Relative cost of a line of vision in age-related macular degeneration. Ophthalmology 2007;114(5):847-854
    13 Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I.The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115(1):116-126
    14 Bansback N, Czoski-Murray C, Carlton J, Lewis G, Hughes L, Espallargues M, Brand C, Brazier J. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res 2007;16(3):533-543. Epub 2006 Nov 22
    15 Bansback N, Davis S, Brazier J.Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. Eye (Lond) 2007;21(12):1455-1463. Epub 2006 Nov 10.
    16 Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A. Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration. Klin Monatsbl Augenheilkd 2007;224(9):727-732
    17 Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008;115(6):1039-1045, e5
    18 Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ. Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology 2003;110(8):1534-1539
    19 Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health 2008;11(4):563-574
    20 Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics 2008;26(1):57-73
    21 Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 2007;114(6):1170-1178
    22 Earnshaw SR. Modeling Treatments for Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: Cost-Effectiveness Methods, in ISPOR 8th Annual European Congress. Florence, Italy. 2005:563-574
    23 Laupacis A, Feeny D, Detsky AS, Tugwell PX.How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Cmaj 1992;146(4):473-481
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Aljoscha S Neubauer, Sandra Liakopoulos, Jan C van Meurs,/et al.Cost-effectiveness of autologous retinal pigment epithelium and choroid translocation in neovascular AMD. Int J Ophthalmol, 2010,3(3):228-233

Copy
Share
Article Metrics
  • Abstract:2272
  • PDF: 1019
  • HTML: 0
  • Cited by: 0
Publication History